Imeik Technology Development Co Rendement FCF

Que fait Imeik Technology Development Co ? Imeik Technology Development Co Ltd is a biotechnology company based in Beijing, China, operating within the healthcare sector. The company focuses on the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. It has established a product technology transformation platform for biomedical materials, including medical chitosan and polylactic acid. Imeik has successfully industrialized injection-type sodium hyaluronate series products and polydioxanone facial implants. Its self-developed products are primarily designed for the repair of facial and neck skin folds, with clinical applications spanning medical cosmetology, surgical repair, and the treatment of metabolic diseases. The company went public on the Shenzhen Stock Exchange on September 28, 2020, with ticker 300896.SZ and ISIN CNE100004868. Imeik currently employs 713 full-time staff and operates exclusively within the Chinese market. Its website is www.imeik.net, providing information on its products and services. The company emphasizes the development and transformation of biomedical materials, aiming to advance biomedicine through its specialized focus on recombinant proteins and peptides. It has developed a range of products that address specific medical and cosmetic needs, contributing to its position in the healthcare industry. Imeik Technology Development Co est l'une des entreprises les plus populaires sur Eulerpool.